Rigel Pharmaceuticals Inc
RIGL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001034842
No open-market purchases or sales by Rigel Pharmaceuticals Inc insiders were filed in the last 90 days; 155 institutions reported holding it in 13F filings for Q2 2026, worth $640.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −2 vs. previous quarter
- 155
- 13F valueReported value at the end of Q2 2026
- $640.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RIGL, Q2 2026
No superinvestor reported holding RIGL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Rigel Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $35.00 | −$87.5K | −19.8%10.1K after | 10b5-1 |
| May 28, 2026 (view filing) | May 26 | 2 days | Ali-Jackson KamilDirector | SSale | −2.50K | $29.17 | −$72.9K | −16.5%12.6K after | 10b5-1 |
| Feb 24, 2026 (view filing) | Feb 20 | 4 days | Moos Walter HDirector | SSale | −4.00K | $36.36 | −$145.4K | −23.9%12.7K after | |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Schorno Dean LEVP & Chief Financial Officer | SSale | −3.77K | $21.38 | −$80.6K | −6.2%57.2K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Santos David AEVP, Chief Commercial Officer | SSale | −3.92K | $21.38 | −$83.8K | −7.0%51.7K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Rodriguez Raul RCEO, President | SSale | −9.35K | $21.40 | −$200.1K | −3.8%239.5K after | 2 lots |
| Feb 6, 2025 (view filing) | Feb 4-5 | 2 days | Furey Raymond J.EVP, GC, CCO & Corp Sec | SSale | −2.79K | $21.41 | −$59.7K | −6.7%38.8K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Santos David AEVP, Chief Commercial Officer | SSale | −14.5K | $1.14 | −$16.5K | −4.0%349.1K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Schorno Dean LEVP & Chief Financial Officer | SSale | −12.6K | $1.14 | −$14.3K | −3.0%402.9K after | 2 lots |
| Feb 6, 2024 (view filing) | Feb 2-5 | 4 days | Rodriguez Raul RCEO, President | SSale | −52.9K | $1.14 | −$60.1K | −2.5%2.04M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Rigel Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | $75.9M | 0.00% | +170,911+9.7% | Added |
| Soleus Capital Management, L.P. | 1,843,504 | $72.1M | 2.49% | +1,833,504+18,335.0% | Added |
| Armistice Capital, LLC | 1,672,000 | $65.4M | 1.81% | +392,000+30.6% | Added |
| State Street Corp | 1,039,994 | $40.7M | 0.00% | −80,244−7.2% | Reduced |
| Vanguard Capital Management LLC | 785,107 | $30.7M | 0.00% | +20,914+2.7% | Added |
| American Century Companies Inc | 741,718 | $29.0M | 0.01% | +197,287+36.2% | Added |
| LSV Asset Management | 721,666 | $28.2M | 0.05% | +120,159+20.0% | Added |
| Acadian Asset Management LLC | 591,686 | $23.1M | 0.03% | −74,740−11.2% | Reduced |
| D. E. Shaw & Co., Inc. | 542,539 | $21.2M | 0.01% | +96,861+21.7% | Added |
| Geode Capital Management, LLC | 483,175 | $18.9M | 0.00% | +42,549+9.7% | Added |